CTMX logo

CytomX Therapeutics (CTMX) EBITDA

Annual EBITDA

-$4.31 M
+$94.58 M+95.64%

December 31, 2023


Summary


Performance

CTMX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCTMXprofitabilitymetrics:

Quarterly EBITDA

$4.54 M
+$12.53 M+156.80%

September 30, 2024


Summary


Performance

CTMX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCTMXprofitabilitymetrics:

TTM EBITDA

$8.55 M
+$933.00 K+12.25%

September 30, 2024


Summary


Performance

CTMX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCTMXprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

CTMX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+95.6%+25.9%+165.3%
3 y3 years+94.5%+25.9%+165.3%
5 y5 years+94.3%+25.9%+165.3%

CTMX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+96.2%-62.5%+107.8%-33.6%+105.8%
5 y5-yearat high+96.9%-62.5%+106.7%-33.6%+105.8%
alltimeall timeat high+96.9%-62.5%+106.7%-33.6%+105.8%

CytomX Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
$4.54 M(-156.8%)
$8.55 M(+12.2%)
Jun 2024
-
-$7.99 M(-165.9%)
$7.62 M(-40.8%)
Mar 2024
-
$12.12 M(<-9900.0%)
$12.87 M(-398.7%)
Dec 2023
-$4.31 M(-95.6%)
-$120.00 K(-103.3%)
-$4.31 M(-67.1%)
Sep 2023
-
$3.61 M(-231.7%)
-$13.09 M(-71.4%)
Jun 2023
-
-$2.74 M(-45.9%)
-$45.78 M(-36.8%)
Mar 2023
-
-$5.06 M(-43.2%)
-$72.49 M(-26.7%)
Dec 2022
-$98.89 M(-12.7%)
-$8.90 M(-69.4%)
-$98.89 M(-33.1%)
Sep 2022
-
-$29.09 M(-1.2%)
-$147.88 M(+5.1%)
Jun 2022
-
-$29.44 M(-6.4%)
-$140.76 M(+8.4%)
Mar 2022
-
-$31.46 M(-45.7%)
-$129.84 M(+14.6%)
Dec 2021
-$113.34 M(+45.4%)
-$57.89 M(+163.6%)
-$113.34 M(+11.7%)
Sep 2021
-
-$21.96 M(+18.5%)
-$101.49 M(+8.2%)
Jun 2021
-
-$18.53 M(+23.9%)
-$93.78 M(+3.3%)
Mar 2021
-
-$14.95 M(-67.5%)
-$90.76 M(+16.4%)
Dec 2020
-$77.97 M(-43.9%)
-$46.05 M(+223.3%)
-$77.97 M(-21.5%)
Sep 2020
-
-$14.24 M(-8.2%)
-$99.27 M(-9.8%)
Jun 2020
-
-$15.52 M(+619.7%)
-$110.07 M(-12.0%)
Mar 2020
-
-$2.16 M(-96.8%)
-$125.12 M(-9.9%)
Dec 2019
-$138.88 M
-$67.36 M(+169.0%)
-$138.88 M(+43.4%)
Sep 2019
-
-$25.04 M(-18.1%)
-$96.83 M(+2.5%)
DateAnnualQuarterlyTTM
Jun 2019
-
-$30.57 M(+92.1%)
-$94.46 M(+23.2%)
Mar 2019
-
-$15.91 M(-37.1%)
-$76.68 M(+0.9%)
Dec 2018
-$75.99 M(+81.1%)
-$25.31 M(+11.7%)
-$75.99 M(+55.5%)
Sep 2018
-
-$22.67 M(+77.2%)
-$48.86 M(+33.0%)
Jun 2018
-
-$12.79 M(-15.9%)
-$36.74 M(-24.9%)
Mar 2018
-
-$15.22 M(-935.7%)
-$48.95 M(+16.7%)
Dec 2017
-$41.95 M(-26.6%)
$1.82 M(-117.3%)
-$41.95 M(-26.2%)
Sep 2017
-
-$10.55 M(-57.8%)
-$56.84 M(-6.5%)
Jun 2017
-
-$25.00 M(+204.2%)
-$60.77 M(+22.6%)
Mar 2017
-
-$8.22 M(-37.1%)
-$49.58 M(-12.5%)
Dec 2016
-$57.19 M(+76.4%)
-$13.07 M(-9.7%)
-$56.68 M(+4.2%)
Sep 2016
-
-$14.47 M(+4.8%)
-$54.38 M(+7.2%)
Jun 2016
-
-$13.81 M(-9.8%)
-$50.75 M(+20.8%)
Mar 2016
-
-$15.32 M(+42.1%)
-$42.03 M(+29.6%)
Dec 2015
-$32.43 M(+11.7%)
-$10.78 M(-0.6%)
-$32.43 M(+24.3%)
Sep 2015
-
-$10.84 M(+113.0%)
-$26.09 M(+40.8%)
Jun 2015
-
-$5.09 M(-10.9%)
-$18.53 M(+37.9%)
Mar 2015
-
-$5.71 M(+28.5%)
-$13.44 M(+74.0%)
Dec 2014
-$29.03 M(+104.1%)
-$4.45 M(+35.7%)
-$7.72 M(+135.7%)
Sep 2014
-
-$3.28 M
-$3.28 M
Dec 2013
-$14.22 M
-
-

FAQ

  • What is CytomX Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for CytomX Therapeutics?
  • What is CytomX Therapeutics annual EBITDA year-on-year change?
  • What is CytomX Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for CytomX Therapeutics?
  • What is CytomX Therapeutics quarterly EBITDA year-on-year change?
  • What is CytomX Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for CytomX Therapeutics?
  • What is CytomX Therapeutics TTM EBITDA year-on-year change?

What is CytomX Therapeutics annual EBITDA?

The current annual EBITDA of CTMX is -$4.31 M

What is the all time high annual EBITDA for CytomX Therapeutics?

CytomX Therapeutics all-time high annual EBITDA is -$4.31 M

What is CytomX Therapeutics annual EBITDA year-on-year change?

Over the past year, CTMX annual EBITDA has changed by +$94.58 M (+95.64%)

What is CytomX Therapeutics quarterly EBITDA?

The current quarterly EBITDA of CTMX is $4.54 M

What is the all time high quarterly EBITDA for CytomX Therapeutics?

CytomX Therapeutics all-time high quarterly EBITDA is $12.12 M

What is CytomX Therapeutics quarterly EBITDA year-on-year change?

Over the past year, CTMX quarterly EBITDA has changed by +$933.00 K (+25.87%)

What is CytomX Therapeutics TTM EBITDA?

The current TTM EBITDA of CTMX is $8.55 M

What is the all time high TTM EBITDA for CytomX Therapeutics?

CytomX Therapeutics all-time high TTM EBITDA is $12.87 M

What is CytomX Therapeutics TTM EBITDA year-on-year change?

Over the past year, CTMX TTM EBITDA has changed by +$21.64 M (+165.33%)